ADAMTS15 | ADAM metallopeptidase with thrombospondin type 1 motif, 15 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS16 | ADAM metallopeptidase with thrombospondin type 1 motif, 16 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS18 | ADAM metallopeptidase with thrombospondin type 1 motif, 18 | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADAMTS19 | ADAM metallopeptidase with thrombospondin type 1 motif, 19 | Enzymes Predicted secreted proteins
| | | | | Group enriched |
ADAMTS4 | ADAM metallopeptidase with thrombospondin type 1 motif, 4 | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif, 5 | Cancer-related genes Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS8 | ADAM metallopeptidase with thrombospondin type 1 motif, 8 | Cancer-related genes Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS9 | ADAM metallopeptidase with thrombospondin type 1 motif, 9 | Cancer-related genes Enzymes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTSL2 | ADAMTS-like 2 | Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTSL4 | ADAMTS-like 4 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTSL5 | ADAMTS-like 5 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADARB2 | Adenosine deaminase, RNA-specific, B2 (non-functional) | Predicted intracellular proteins
| | | | | Tissue enhanced |
ADCK3 | AarF domain containing kinase 3 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted intracellular proteins
| | | | | Tissue enriched |
ADCY1 | Adenylate cyclase 1 (brain) | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
ADCY10 | Adenylate cyclase 10 (soluble) | Cytoskeleton related proteins Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
ADCY2 | Adenylate cyclase 2 (brain) | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADCY5 | Adenylate cyclase 5 | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADCY8 | Adenylate cyclase 8 (brain) | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
ADCYAP1 | Adenylate cyclase activating polypeptide 1 (pituitary) | Predicted secreted proteins
| | | | | Tissue enhanced |
ADCYAP1R1 | Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Group enriched |
ADD2 | Adducin 2 (beta) | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Group enriched |
ADGB | Androglobin | Enzymes Predicted intracellular proteins
| | | | | Group enriched |
ADH1A | Alcohol dehydrogenase 1A (class I), alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
ADH1C | Alcohol dehydrogenase 1C (class I), gamma polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
ADH4 | Alcohol dehydrogenase 4 (class II), pi polypeptide | Enzymes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
ADH6 | Alcohol dehydrogenase 6 (class V) | Enzymes Predicted intracellular proteins
| | | | | Tissue enriched |
ADH7 | Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide | Enzymes Predicted intracellular proteins
| | | | | Tissue enriched |
ADHFE1 | Alcohol dehydrogenase, iron containing, 1 | Enzymes Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
ADIG | Adipogenin | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADIPOQ | Adiponectin, C1Q and collagen domain containing | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADM2 | Adrenomedullin 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
ADORA1 | Adenosine A1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ADORA2B | Adenosine A2b receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADORA3 | Adenosine A3 receptor | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADPRHL1 | ADP-ribosylhydrolase like 1 | Predicted intracellular proteins
| | | | | Group enriched |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1B | Adrenoceptor alpha 1B | Cancer-related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1D | Adrenoceptor alpha 1D | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA2C | Adrenoceptor alpha 2C | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB3 | Adrenoceptor beta 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADSSL1 | Adenylosuccinate synthase like 1 | Enzymes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
ADTRP | Androgen-dependent TFPI-regulating protein | Predicted membrane proteins
| | | | | Tissue enhanced |
AF131216.1 | HCG1991042 {ECO:0000313|EMBL:EAW65606.1} | Predicted intracellular proteins
| | | | | Tissue enriched |
AFAP1L2 | Actin filament associated protein 1-like 2 | Predicted intracellular proteins
| | | | | Tissue enhanced |
AFF2 | AF4/FMR2 family, member 2 | Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
AFM | Afamin | Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
AFP | Alpha-fetoprotein | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | Predicted intracellular proteins
| | | | | Tissue enriched |